EcoDrugPlus

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSAPEG00000014612
Gene Symbol: PSMB8A
1 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSAPEG00000014578
Gene Symbol: PSMB9A
1 Cross references
209 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSAPEG00000001498
Gene Symbol: PSMD2
1 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSAPEG00000007908
Gene Symbol: PSMD4A
1 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSAPEG00000003043
Gene Symbol: PSMD4B
1 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1a

Ensembl ID : ENSAPEG00000015694
Gene Symbol: PSMC1A
1 Cross references
318 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSAPEG00000019951
Gene Symbol: PSMC2
1 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSAPEG00000005839
Gene Symbol: PSMC3
1 Cross references
192 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSAPEG00000005528
Gene Symbol: PSMC3
1 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSAPEG00000021513
Gene Symbol: PSMC4
1 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSAPEG00000018680
Gene Symbol: PSMC5
1 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSAPEG00000004978
Gene Symbol: PSMC6
1 Cross references
241 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).